title: [Psychosomatic aspects of therapy in patients with ischemic heart disease of behavioral type A].
abstract: Forty-five patients aged 34 to 67 years who had coronary heart disease (CHD) were examined. Anaprilin was given in a dose of up to 120 mg daily. Concurrently with positive changes in the anginal syndrome there were improved sleep, decreases in hot temper, irritability, anxiety, phobic manifestations, hypochondrical trends, and neurotic asthenization, increased working and social orientation. During anaprilin therapy, cardialgias reduced or disappeared, the incidence of arrhythmia decreased. There was a reduction in the personality profile in the scales "neurotic triad" and "psychoasthenia", significantly diminished reactive anxiety, and a decrease in the blood levels of aldosterone, cortisol, triiodothyronine, and thyroxine. Thus, supplementation of anapriline to the combined therapy for patients with CHD of behavioral type A (BTA) positive affected the clinical course of the disease. Hormonal disorders in BTA CHA may be eliminated by anaprilin. Configuration of the personality profile was leveled in patients with CHA of "coronary" type.
authors.forename: V N
authors.initials: VN
authors.lastname: Fedorets
authors.forename: V G
authors.initials: VG
authors.lastname: Radchenko
authors.forename: A A
authors.initials: AA
authors.lastname: Skoromets
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000453:epidemiology*; D011433:Propranolol / Q000627:therapeutic use*; D011602:Psychophysiologic Disorders / Q000453:epidemiology*; D014434:Type A Personality; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D014665:Vasodilator Agents; D011433:Propranolol